SAGE Veterinary Centers
Specialty hospital / research center
2 current cancer treatment or research opportunities
About SAGE Veterinary Centers
SAGE Veterinary Centers is the participating hospital named in the current study listing below. The hospital is part of the Ethos Veterinary Health network, while Ethos Discovery coordinates the research program. Screening, enrollment and required visits are handled by the participating hospital; owners should confirm that the location is still enrolling before making travel plans.
SAGE Veterinary Centers official website →
Who the current listings are forDogs
Cancer types currently listedHemangiosarcoma, Lymphoma
Where visits take placeSAGE Veterinary Centers, 600 Alabama St, San Francisco, CA 94110
Current options at SAGE Veterinary Centers
Open an option to see who may qualify, locations, costs or coverage, contact details and the official source.
SOLID-Relapse — treatment study for dogs with relapsed multicentric nodal lymphoma
Colorado Animal Specialty & Emergency (CASE) / Ethos Discovery · USA
Currently enrolling
What is being offered: Randomized lymphoma treatment under an Ethos oncologist plus genomic/biomarker sampling
Who may qualify: Confirmed cancer diagnosis required; Prior chemo; Active tumor required; Lymphoma response: First relapse after remission; More than one relapse; Planned chemo
Costs / coverage: 🟡 Partially funded. Study provides screening and scheduled laboratory testing plus up to $4,500 toward chemotherapy, exams, diagnostics and medications for chemotherapy-related side effects.
Contact: CASE Clinical Trials — CASEtrials@ethosvet.com; 303-545-2273
Location
- SAGE Veterinary Centers, 600 Alabama St, San Francisco, CA 94110
Official study / enrollment information →
Ethos-PUSH precision-medicine umbrella study for splenic hemangiosarcoma
Ethos Discovery / multicenter specialty hospitals · USA
Open / currently enrolling
What is being offered: Phase 1 splenectomy/hemoabdomen study; dogs confirmed with non-metastatic splenic HSA can continue to fully funded active-treatment Phase 2, with treatment assigned among doxorubicin, doxorubicin+rapamycin, doxorubicin+sorafenib, or oral paclitaxel regimens.
Who may qualify: No metastasis; Active tumor required; Splenic primary; Planned surgery; Pre splenectomy; Min weight kg exclusive: 5; Max weight kg exclusive: 45
Costs / coverage: 🟡 Partially funded overall. Phase 1 provides $1,000 toward splenectomy; owners remain responsible for other initial surgical/screening costs. Dogs subsequently confirmed with splenic HSA and no metastases can enter fully funded Phase 2 (> $10,000 value). Sponsor states up to $3,000 for study-related side effects.
Contact: Ethos Discovery enrollment form / participating hospital; CASE: 303-545-2273
Location
- SAGE Veterinary Centers, 600 Alabama St, San Francisco, CA 94110
Official study / enrollment information →
Before you contact the center
A listing here does not mean every pet will qualify. Enrollment can change, and the study team makes the final decision after reviewing your pet’s diagnosis, records and previous treatment.
Have the pathology report, recent imaging and treatment history ready. Ask whether a referral is required, which visits must happen in person and what the study pays for before making travel plans.
Check all options for your pet →
Free to use. No registration or paid report.
